Evidence map›Paper›PMID 35687811›Full record

ArticleThe journal of trauma and acute care surgery2022

Plasma-based assays distinguish hyperfibrinolysis and shutdown subgroups in trauma-induced coagulopathy.

Michael A Lawson, Lori A Holle, Nathan E Dow, Grant Hennig, Bas de Laat, Hunter B Moore, Ernest E Moore, Mitchell J Cohen, Beth A Bouchard, Kalev Freeman and 1 more

Open access · greenAbstract read
In one paragraph

Article in The journal of trauma and acute care surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Deconstructing fibrin(ogen) structure.Journal of thrombosis and haemostasis : JTH · 2025
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Michael A LawsonFrom the Department of Surgery (M.A.L., N.E.D., K.F.), University of Vermont, Burlington, Vermont; Department of Pathology and Laboratory Medicine and UNC Blood Research Center (L.A.H., A.S.W.), University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Department of Pharmacology (G.H.), University of Vermont, Burlington, Vermont; Synapse Research Institute (B.D.L.), Maastricht, the Netherlands; Department of Surgery (H.B.M., E.E.M., M.J.C.), University of Colorado School of Medicine (E.E.M.), Aurora; Ernest E Moore Shock Trauma Center at Denver Health (E.E.M.), Denver, Colorado; and Department of Biochemistry and Laboratory for Clinical Biochemistry Research (B.A.B.), University of Vermont, Burlington, Vermont.
Lori A Holle
Nathan E Dow
Grant Hennig
Bas de Laat
Hunter B Moore
Ernest E Moore
Mitchell J Cohen
Beth A Bouchard
Kalev Freeman
Alisa S Wolberg
University of Vermont · USUniversity of Colorado Denver · USUniversity of North Carolina at Chapel Hill · USDenver Health Medical Center · USSynapse (Netherlands) · NL

Funding

ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating CenterOT2HL156812 · NHLBI · RESEARCH TRIANGLE INSTITUTE · PI NOLEN, TRACY L, THOMAS, SONIA M · 2020 to 2024
$1270.7M
Fibrinogen and Factor XIII in Venous ThrombosisR01HL126974 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Alisa S. Wolberg · 2016 to 2026
$4.4M
R35 Undergraduate Research SupplementR35GM144099 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Kalev Freeman · 2022 to 2026
$2.2M
Nikon A1R-ER Confocal Microscope for the Microscopy Imaging CenterS10OD025030 · OD · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI TAATJES, DOUGLAS J. · 2018 to 2018
$557k
NHLBI NIH HHS OT2 HL156812NHLBI NIH HHS R01 HL126974NIGMS NIH HHS R35 GM144099NIH HHS S10 OD025030
6 · The paper itself

Abstract

backgroundTrauma patients with abnormal fibrinolysis have increased morbidity and mortality. Knowledge of mechanisms differentiating fibrinolytic phenotypes is important to optimize treatment. We hypothesized that subjects with abnormal fibrinolysis identified by whole blood viscoelastometry can also be distinguished by plasma thrombin generation, clot structure, fibrin formation, and plasmin generation measurements.

methodsPlatelet-poor plasma (PPP) from an observational cross-sectional trauma cohort with fibrinolysis shutdown (% lysis at 30 minutes [LY30] < 0.9, n = 11) or hyperfibrinolysis (LY30 > 3%, n = 9) defined by whole blood thromboelastography were studied. Noninjured control subjects provided comparative samples. Thrombin generation, fibrin structure and formation, and plasmin generation were measured by fluorescence, confocal microscopy, turbidity, and a fluorescence-calibrated plasmin assay, respectively, in the absence/presence of tissue factor or tissue plasminogen activator (tPA).

resultsWhereas spontaneous thrombin generation was not detected in PPP from control subjects, PPP from hyperfibrinolysis or shutdown patients demonstrated spontaneous thrombin generation, and the lag time was shorter in hyperfibrinolysis versus shutdown. Addition of tissue factor masked this difference but revealed increased thrombin generation in hyperfibrinolysis samples. Compared with shutdown, hyperfibrinolysis PPP formed denser fibrin networks. In the absence of tPA, the fibrin formation rate was faster in shutdown than hyperfibrinolysis, but hyperfibrinolysis clots lysed spontaneously; these differences were masked by addition of tPA. Tissue plasminogen activator-stimulated plasmin generation was similar in hyperfibrinolysis and shutdown samples. Differences in LY30, fibrin structure, and lysis correlated with pH.

conclusionThis exploratory study using PPP-based assays identified differences in thrombin generation, fibrin formation and structure, and lysis in hyperfibrinolysis and shutdown subgroups. These groups did not differ in their ability to promote tPA-triggered plasmin generation. The ability to characterize these activities in PPP facilitates studies to identify mechanisms that promote adverse outcomes in trauma. LEVEL OF EVIDENCE: Prognostic/Epidemiological; Level III.

Indexed as

Blood Coagulation DisordersTissue Plasminogen ActivatorCross-Sectional StudiesFibrinFibrinolysinFibrinolysisHumansThrombinThromboplastinFibrinFibrinolysinThrombinThromboplastinTissue Plasminogen Activator

Identifiers

PMID35687811
PMCPMC9613511
OpenAlexW4281893211

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.